When applying a drug delivery technology to a marketed product, the resulting formulation should result in increased sales or otherwise give a product a competitive advantage. If not, drug delivery companies may find their would-be partners unwilling to invest in such projects. An example is Aradigm Corp., which saw 25 percent of its market cap erased last Monday when partner Genentech Inc. elected not to proceed with the development of